NSAIDs for the Chemoprevention of Alzheimer’s Disease

  • Christine A. Szekely
  • Terrence Town
  • Peter P. Zandi
Part of the Subcellular Biochemistry book series (SCBI, volume 42)

Abstract

Epidemiologic and laboratory studies suggest that non-steroidal anti-inflammatory drug (NSAID) use reduces the risk of Alzheimer’s disease (AD). Initial reports in the early 1990’s indicated that a history of arthritis, a presumed surrogate of NSAID use, was associated with a lower risk of AD. [1] These reports were followed by epidemiologic studies in which NSAID use was assessed directly and the majority of these reports confirmed the inverse association with risk for AD. [2,3] Postmortem studies in humans [4], studies in animal models of AD [5,6], and in vitro studies [7,8] generally support the notion that NSAIDs can reduce the deleterious inflammation which surrounds amyloid beta (Aβ) plaques in the AD brain. In addition, some studies conducted in vitro and in rodents point to a subgroup of NSAIDs that may work by inhibiting amyloidogenic APP metabolism rather than through traditional anti-inflammatory mechanisms. [9-11] This novel property of NSAIDs is currently being explored in epidemiologic studies. Results from randomized clinical trials of NSAIDs and established AD and one trial on secondary prevention have not been promising and there have been no prevention trials completed. The feasibility of using NSAIDs as a chemopreventive agent in AD is discussed

References

  1. 1.
    McGeer PL,Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology. 1996;47(2):425–432.PubMedGoogle Scholar
  2. 2.
    Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. BMJ. 2003;327:128–132.PubMedCrossRefGoogle Scholar
  3. 3.
    Szekely CA, Thorne JE, Zandi PP et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer’s disease: a systematic review. Neuroepidemiology. 2004;23:159–169.PubMedCrossRefGoogle Scholar
  4. 4.
    Mackenzie IR, Munoz DG. Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch Neurol. 2001;58(3):517–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Lim GP, Yang F, Chu T et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci. 2000;20(15):5709–5714.PubMedGoogle Scholar
  6. 6.
    Lim GP, Yang F, Chu T et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging. 2001;22(6):983–991.PubMedCrossRefGoogle Scholar
  7. 7.
    Dzenko KA, Weltzien RB, Pachter JS. Suppression of A beta-induced monocyte neurotoxicity by antiinflammatory compounds. J Neuroimmunol. 1997;80(1-2):6–12.PubMedCrossRefGoogle Scholar
  8. 8.
    Netland EE, Newton JL, Majocha RE, Tate BA. Indomethacin reverses the microglial response to amyloid beta-protein. Neurobiol Aging. 1998;19(3):201–204.PubMedCrossRefGoogle Scholar
  9. 9.
    Eriksen JL, Sagi SA, Smith TE et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003;112(3):440–449.PubMedCrossRefGoogle Scholar
  10. 10.
    Sagi SA, Weggen S, Eriksen J, Golde TE, Koo EH. The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production. J Biol Chem. 2003;278(34):31825–31830.PubMedCrossRefGoogle Scholar
  11. 11.
    Weggen S, Eriksen JL, Das P et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414(6860):212–216.PubMedCrossRefGoogle Scholar
  12. 12.
    Brookmeyer R, Gray S. Methods for projecting the incidence and prevalence of chronic diseases in aging populations: application to Alzheimer’s disease. Stat Med. 2000;19(11-12):1481–1493.PubMedCrossRefGoogle Scholar
  13. 13.
    Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60(8):1119–1122.PubMedCrossRefGoogle Scholar
  14. 14.
    Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry. 1998;55(9):809–815.PubMedCrossRefGoogle Scholar
  15. 15.
    U.S. Census Bureau. Annual projections of the resident population by age, sex, race, and hispanic origin: lowest, middle, highest series and zero international migration series, 1999 to 2100. [http://www.census.gov/publication/www/projections/natdet-D1A.html] Accessed 07 April 2004.Google Scholar
  16. 16.
    Centers for Disease Control. Public health and aging: Trends in aging – United States and worldwide. Morbidity and Mortality Weekly Report. 2003;52(6):101–106.Google Scholar
  17. 17.
    Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A. 1988;85(11):4051–4055.PubMedCrossRefGoogle Scholar
  18. 18.
    Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351–357.PubMedCrossRefGoogle Scholar
  19. 19.
    Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741–766.PubMedGoogle Scholar
  20. 20.
    Selkoe DJ. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med. 2004;140(8):627–638.PubMedGoogle Scholar
  21. 21.
    Jarrett JT, Berger EP, Lansbury PT Jr. The C-terminus of the beta protein is critical in amyloidogenesis. Ann N Y Acad Sci. 1993;695:144–148.PubMedCrossRefGoogle Scholar
  22. 22.
    Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron. 1994;13(1):45–53.PubMedCrossRefGoogle Scholar
  23. 23.
    Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis. 1996;3(1):16–32.PubMedCrossRefGoogle Scholar
  24. 24.
    Selkoe DJ. Toward a comprehensive theory for Alzheimer’s disease. Hypothesis: Alzheimer’s disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci. 2000;924:17–25.PubMedCrossRefGoogle Scholar
  25. 25.
    McGeer PL, McGeer EG. Mechanisms of cell death in Alzheimer disease–immunopathology. J Neural Transm Suppl. 1998;54:159–166.PubMedGoogle Scholar
  26. 26.
    Akiyama H, Barger S, Barnum S et al. Inflammation and Alzheimer’s disease. Neurobiol Aging. 2000;21(3):383–421.PubMedCrossRefGoogle Scholar
  27. 27.
    McGeer EG, McGeer PL. Inflammatory processes in Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(5):741–749.PubMedCrossRefGoogle Scholar
  28. 28.
    Eikelenboom P, Bate C, Van Gool WA et al. Neuroinflammation in Alzheimer’s disease and prion disease. Glia. 2002;40(2):232–239.PubMedCrossRefGoogle Scholar
  29. 29.
    Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. Immune reactive cells in senile plaques and cognitive decline in Alzheimer’s disease. Neurobiol Aging. 2003;24(2):321–331.PubMedCrossRefGoogle Scholar
  30. 30.
    Cagnin A, Brooks DJ, Kennedy AM et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358(9280):461–467.PubMedCrossRefGoogle Scholar
  31. 31.
    Yasojima K, Schwab C, McGeer EG, McGeer PL. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease. Brain Res. 2000;887(1):80–89.PubMedCrossRefGoogle Scholar
  32. 32.
    Rogers J, Cooper NR, Webster S et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A. 1992;89(21):10016–10020.PubMedCrossRefGoogle Scholar
  33. 33.
    Bradt BM, Kolb WP, Cooper NR. Complement-dependent proinflammatory properties of the Alzheimer’s disease beta-peptide. J Exp Med. 1998;188(3):431–438.PubMedCrossRefGoogle Scholar
  34. 34.
    Mehlhorn G, Hollborn M, Schliebs R. Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int J Dev Neurosci. 2000;18(4-5):423–431.PubMedCrossRefGoogle Scholar
  35. 35.
    Benzing WC, Wujek JR, Ward EK et al. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol Aging. 1999;20(6):581–589.PubMedCrossRefGoogle Scholar
  36. 36.
    Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232–235.PubMedGoogle Scholar
  37. 37.
    Meade EA, Smith WL, Dewitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993;268(9):6610–6614.PubMedGoogle Scholar
  38. 38.
    DuBois RN, Abramson SB, Crofford L et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12(12):1063–1073.PubMedGoogle Scholar
  39. 39.
    Couzin J. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science. 2004;306(5695):384–385.PubMedCrossRefGoogle Scholar
  40. 40.
    Drazen JM. COX-2 inhibitors–a lesson in unexpected problems. N Engl J Med. 2005;352(11): 1131–1132.PubMedCrossRefGoogle Scholar
  41. 41.
    Psaty BM, Furberg CD. COX-2 inhibitors–lessons in drug safety. N Engl J Med. 2005;352(11):1133–1135.PubMedCrossRefGoogle Scholar
  42. 42.
    Mackenzie IR, Munoz DG. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology. 1998;50(4):986–90.PubMedGoogle Scholar
  43. 43.
    Halliday GM, Shepherd CE, McCann H et al. Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch Neurol. 2000;57(6):831–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Jantzen PT, Connor KE, DiCarlo G et al. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci. 2002;22(6):2246–2254.PubMedGoogle Scholar
  45. 45.
    Quinn J, Montine T, Morrow J, Woodward WR, Kulhanek D, Eckenstein F. Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer’s disease. J Neuroimmunol. 2003;137(1-2):32–41.PubMedCrossRefGoogle Scholar
  46. 46.
    Yan Q, Zhang J, Liu H et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer’s disease. J Neurosci. 2003;23(20):7504–7509.PubMedGoogle Scholar
  47. 47.
    Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001;21(21):8370–8377.PubMedGoogle Scholar
  48. 48.
    Kerr ML, Small DH. Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer’s disease: function, regulation of proteolysis, and implications for drug development. J Neurosci Res. 2005;80(2):151–159.PubMedCrossRefGoogle Scholar
  49. 49.
    Weggen S, Eriksen JL, Sagi SA et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem. 2003;278(34):31831–31837.PubMedCrossRefGoogle Scholar
  50. 50.
    Lanz TA, Fici GJ, Merchant KM. Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J Pharmacol Exp Ther. 2005;312(1):399–406.PubMedCrossRefGoogle Scholar
  51. 51.
    Beher D, Clarke EE, Wrigley JD et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J Biol Chem. 2004;279(42):43419–43426.PubMedCrossRefGoogle Scholar
  52. 52.
    Morihara T, Chu T, Ubeda O, Beech W, Cole GM. Selective inhibition of Abeta42 production by NSAID R-enantiomers. J Neurochem. 2002;83(4):1009–1012.PubMedCrossRefGoogle Scholar
  53. 53.
    Takahashi Y, Hayashi I, Tominari Y et al. Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J Biol Chem. 2003;278(20):18664–18670.PubMedCrossRefGoogle Scholar
  54. 54.
    Gasparini L, Rusconi L, Xu H, del SP, Ongini E. Modulation of beta-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures. J Neurochem. 2004;88(2):337–348.PubMedCrossRefGoogle Scholar
  55. 55.
    Peretto I, Radaelli S, Parini C et al. Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion. J Med Chem. 2005;48(18):5705–5720.PubMedCrossRefGoogle Scholar
  56. 56.
    Lleo A, Berezovska O, Herl L et al. Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med. 2004;10(10):1065–1066.PubMedCrossRefGoogle Scholar
  57. 57.
    Jankowsky JL, Slunt HH, Gonzales V et al. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med. 2005;2(12):e355.PubMedCrossRefGoogle Scholar
  58. 58.
    Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T. Alzheimer’s disease: a study of epidemiological aspects. Ann Neurol. 1984;15(4):335–41.PubMedCrossRefGoogle Scholar
  59. 59.
    French LR, Schuman LM, Mortimer JA, Hutton JT, Boatman RA, Christians B. A case-control study of dementia of the Alzheimer type. Am J Epidemiol. 1985;121(3):414–21.PubMedGoogle Scholar
  60. 60.
    Jenkinson ML, Bliss MR, Brain AT, Scott DL. Rheumatoid arthritis and senile dementia of the Alzheimer’s type. Br J Rheumatol. 1989;28(1):86–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Graves AB, White E, Koepsell TD et al. A case-control study of Alzheimer’s disease. Ann Neurol. 1990;28(6):766–74.PubMedCrossRefGoogle Scholar
  62. 62.
    Broe GA, Henderson AS, Creasey H et al. A case-control study of Alzheimer’s disease in Australia. Neurology. 1990;40(11):1698–707.PubMedGoogle Scholar
  63. 63.
    McGeer PL, McGeer E, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet. 1990;335(8696):1037.PubMedCrossRefGoogle Scholar
  64. 64.
    Beard CM, Kokman E, Kurland LT. Rheumatoid arthritis and susceptibility to Alzheimer’s disease. Lancet. 1991;337(8754):1426.PubMedCrossRefGoogle Scholar
  65. 65.
    McGeer, P. L., Harada, N., Kimura, H., and McGeer, E. G. Prevalence of dementia amongst elderly Japanese with leprosy: Apparent effect of chronic drug therapy. Dementia. 1992;3(3):146–149.Google Scholar
  66. 66.
    Li G, Shen YC, Li YT, Chen CH, Zhau YW, Silverman JM. A case-control study of Alzheimer’s disease in China. Neurology. 1992;42(8):1481–8.PubMedGoogle Scholar
  67. 67.
    Myllykangas-Luosujarvi R, Isomaki H. Alzheimer’s disease and rheumatoid arthritis. Br J Rheumatol. 1994;33(5):501–2.PubMedCrossRefGoogle Scholar
  68. 68.
    Lucca U, Tettamanti M, Forloni G, Spagnoli A. Nonsteroidal antiinflammatory drug use in Alzheimer’s disease. Biol Psychiatry. 1994;36(12):854–6.PubMedCrossRefGoogle Scholar
  69. 69.
    Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MM, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer’s disease? The Rotterdam Study. Neurology. 1995;45(8):1441–5.PubMedGoogle Scholar
  70. 70.
    Breitner JC, Welsh KA, Helms MJ et al. Delayed onset of Alzheimer’s disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging. 1995;16(4):523–30.PubMedCrossRefGoogle Scholar
  71. 71.
    Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer’s disease. Neurology. 1995;45(1):51–5.PubMedGoogle Scholar
  72. 72.
    Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer’s disease and duration of NSAID use. Neurology. 1997;48(3):626–32.PubMedGoogle Scholar
  73. 73.
    Beard CM, Waring SC, O’Brien PC, Kurland LT, Kokmen E. Nonsteroidal anti-inflammatory drug use and Alzheimer’s disease: a case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin Proc. 1998;73(10):951–5.PubMedGoogle Scholar
  74. 74.
    in ’t Veld BA, Launer LJ, Hoes AW et al. NSAIDs and incident Alzheimer’s disease. The Rotterdam Study. Neurobiol Aging. 1998;19(6):607–11.PubMedCrossRefGoogle Scholar
  75. 75.
    Anthony JC, Breitner JC, Zandi PP et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology. 2000;54(11):2066–71.PubMedGoogle Scholar
  76. 76.
    Broe GA, Grayson DA, Creasey HM et al. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol. 2000;57(11):1586–91.PubMedCrossRefGoogle Scholar
  77. 77.
    in ’t Veld BA, Ruitenberg A, Hofman A et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med. 2001;345(21):1515–21.CrossRefGoogle Scholar
  78. 78.
    Lindsay J, Laurin D, Verreault R et al. Risk factors for Alzheimer’s disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol. 2002;156(5):445–453.PubMedCrossRefGoogle Scholar
  79. 79.
    Wolfson C, Perrault A, Moride Y, Esdaile JM, Abenhaim L, Momoli F. A case-control analysis of nonsteroidal anti-inflammatory drugs and Alzheimer’s disease: are they protective? Neuroepidemiology. 2002;21(2):81–86.PubMedCrossRefGoogle Scholar
  80. 80.
    Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology. 2002;59(6):880–886.PubMedGoogle Scholar
  81. 81.
    Landi F, Cesari M, Onder G, Russo A, Torre S, Bernabei R. Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients. Am J Geriatr Psychiatry. 2003;11(2):179–185.PubMedCrossRefGoogle Scholar
  82. 82.
    Cornelius C, Fastbom J, Winblad B, Viitanen M. Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population. Neuroepidemiology. 2004;23(3):135–143.PubMedCrossRefGoogle Scholar
  83. 83.
    Nilsson SE, Johansson B, Takkinen S et al. Does aspirin protect against Alzheimer’s dementia? A study in a Swedish population-based sample aged > or = 80 years. Eur J Clin Pharmacol. 2003;59(4):313–319.PubMedCrossRefGoogle Scholar
  84. 84.
    The Canadian Study of Health and Aging: risk factors for Alzheimer’s disease in Canada. Neurology. 1994;44(11):2073–80.Google Scholar
  85. 85.
    Breitner JC, Gau BA, Welsh KA et al. Inverse association of anti-inflammatory treatments and Alzheimer’s disease: initial results of a co-twin control study. Neurology. 1994;44(2):227–32.PubMedGoogle Scholar
  86. 86.
    Stata Statistical Software: Release 8.0. College Station, Texas: Stata Corporation; 2003.Google Scholar
  87. 87.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-III-R. 3rd, revised ed. Washington, DC: American Psychiatric Association;1987.Google Scholar
  88. 88.
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939–944.PubMedGoogle Scholar
  89. 89.
    Breteler MB, in ’t Veld BA, Hofman A, and Stricker BH. AB-42 peptide lowering NSAIDs and Alzheimer’s disease. Neurobiol Aging. 2002;23(S1):S286Google Scholar
  90. 90.
    Zandi PP, Szekely CA, Green RC, Breitner JC, Welsh-Bohmer KA. Pooled analysis of the association between different NSAIDs and AD: Preliminary findings. Neurobiol Aging. 2004;25(S2):S5.CrossRefGoogle Scholar
  91. 91.
    Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol. 1999;149(11):981–983.PubMedGoogle Scholar
  92. 92.
    Psaty BM, Koepsell TD, Lin D et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc. 1999;47(6):749–754.PubMedGoogle Scholar
  93. 93.
    Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health. 1998;19:55–72.PubMedCrossRefGoogle Scholar
  94. 94.
    Stricker BH, Hofman A, Breteler MB. Letter to the Editor: Nonsteroidal drugs and Alzheimer’s disease. N Engl J Med. 2002;346(15):1171–1173.CrossRefGoogle Scholar
  95. 95.
    Rogers J, Kirby LC, Hempelman SR et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology. 1993;43(8):1609–1611.PubMedGoogle Scholar
  96. 96.
    Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology. 1999;53(1):197–201.PubMedGoogle Scholar
  97. 97.
    Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer’s disease. Neurology. 2002;58(7):1050–1054.PubMedGoogle Scholar
  98. 98.
    Aisen PS, Schafer KA, Grundman M et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289(21):2819–2826.PubMedCrossRefGoogle Scholar
  99. 99.
    Reines SA, Block GA, Morris JC et al. Rofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62(1):66–71.PubMedCrossRefGoogle Scholar
  100. 100.
    Sainati S, Ingram D, Talwalker S, Geis G. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer’s Disease. 6th International Stockholm-Springfield Symposium of Advances in Alzheimer’s Therapy; 2000; Stockholm, Sweden.Google Scholar
  101. 101.
    Black SE, Wilcock G, Haworth J, et al. A placebo-controlled, double-blind trial of the selective Abeta42-lowering agent Flurizan in patients with mild to moderate Alzheimer’s disease: Efficacy, safety, and follow-on results. 2005. Program No. 585.6. Washington, DC: Society for Neuroscience.Google Scholar
  102. 102.
    www.clinicaltrials.gov. Curcumin in patients with mild to moderate Alzheimer’s disease; Ringman J, Study Director; sponsored by John Douglas French Foundation and ISOA. [www.clinicaltrials.gov]. Accessed 22 March 2006.Google Scholar
  103. 103.
    www.clinicaltrials.gov. Efficacy study of MPC-7869 to treat patients with Alzheimer’s; Laughlin M, Study Director; sponsored by Myriad Pharmaceuticals. [www.clinicaltrials.gov]. Accessed 22 March 2006.Google Scholar
  104. 104.
    www.clinicaltrials.gov. A pilot study of curcumin and ginkgo for treating Alzheimer’s disease; Baum L, Principal Investigator; sponsored by BUPA Foundation and Institute of Chinese Medicine of the Chinese University of Hong Kong. [www.clinicaltrials.gov]. Accessed 22 March 2006.Google Scholar
  105. 105.
    Thal LJ, Ferris SH, Kirby L et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30(6):1204–1215.PubMedCrossRefGoogle Scholar
  106. 106.
    www.clinicaltrials.gov. Anti-inflammatory treatment for age-associated memory impairment: a double-blind placebo-controlled trial; Small GW, Principal Investigator; sponsored by NIMH. [www.clinicaltrials.gov]. Accessed 22 March 2006.Google Scholar
  107. 107.
    ADAPT Steering Committee. Statement from the Steering Committee of the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) to FDA. [www.jhucct.com/adapt/documents.htm]. Accessed 07 April 2006.Google Scholar
  108. 108.
    Myriad Genetics Incorporated. Flurizan™ Alzheimer’s disease phase 3 clinical trial. [http://www.myriad.com/research/trial_ad.php]. Accessed 22 March 2006.Google Scholar
  109. 109.
    Yang F, Lim GP, Begum AN et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005;280(7):5892–5901.PubMedCrossRefGoogle Scholar
  110. 110.
    Martin BK, Meinert CL, Breitner JC. Double placebo design in a prevention trial for Alzheimer’s disease. Control Clin Trials. 2002;23(1):93–99.PubMedCrossRefGoogle Scholar
  111. 111.
    Mukherjee D, Nissen SE, Topol EJ. Cox-2 inhibitors and cardiovascular risk: we defend our data and suggest caution. Cleve Clin J Med. 2001;68(11):963–964.PubMedCrossRefGoogle Scholar
  112. 112.
    Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954–959.PubMedCrossRefGoogle Scholar
  113. 113.
    Solomon SD, McMurray JJ, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071–1080.PubMedCrossRefGoogle Scholar
  114. 114.
    Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092–1102.PubMedCrossRefGoogle Scholar
  115. 115.
    Federal Drug Administration. FDA statement on naproxen. December 20 2004. [http://www.fda.gov/bbs/topics/news/2004/NEW01148.html]. Accessed 18 June 2005.Google Scholar
  116. 116.
    Buring JE. Special issues related to randomized trials of primary prevention. Epidemiol Rev. 2002;24(1):67–71.PubMedCrossRefGoogle Scholar
  117. 117.
    Sesso HD, Gaziano JM, VanDenburgh M, Hennekens CH, Glynn RJ, Buring JE. Comparison of baseline characteristics and mortality experience of participants and nonparticipants in a randomized clinical trial: the Physicians’ Health Study. Control Clin Trials. 2002;23(6):686–702.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2007

Authors and Affiliations

  • Christine A. Szekely
    • 1
  • Terrence Town
    • 2
  • Peter P. Zandi
    • 1
  1. 1.Department of Mental HealthJohns Hopkins Bloomberg School of Public HealthBaltimore
  2. 2.Section of ImmunobiologyYale University School of MedicineNew Haven

Personalised recommendations